ART-123 Asahi Kasei.
Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism [169907]. By September 2000, it had entered phase III trials [383525]. A patent, US-05916874, claiming a method for treating liver injury and whose composition comprises a thrombomodulin, was published in 1999 by the company.
Khorchidi
Sascha
S
Department of Radiology, University of Tübingen, Germany. sascha.khorchidi@uni-tuebingen.de
Bantleon
Ruediger
R
Kehlbach
Rainer
R
Tepe
Gunnar
G
Wiskirchen
Jakub
J
Duda
Stephan H
SH
D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000188:drug therapy*; D018180:Thrombomodulin / Q000378:metabolism / Q000627:therapeutic use*
C472045:ART123; D011994:Recombinant Proteins; D018180:Thrombomodulin